Gemvert Tablet contains a combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg, formulated to manage and prevent symptoms associated with motion sickness, vertigo, and balance disorders. Cinnarizine, a selective calcium channel blocker, acts by inhibiting vestibular sensory input to the brain, thereby reducing nausea and dizziness. Dimenhydrinate, an antihistamine with anticholinergic properties, further alleviates nausea, vomiting, and motion-induced discomfort by blocking histamine H1 receptors and exerting central nervous system depressant effects. The synergistic action of these active ingredients makes Gemvert effective in controlling vestibular disturbances and improving patient comfort during travel or in conditions such as Meniere’s disease. It is indicated for the prophylaxis and treatment of motion sickness, vertigo of vestibular origin, and associated nausea and vomiting. Gemvert should be used with caution in patients with glaucoma, asthma, or prostatic hypertrophy, and is contraindicated in individuals with hypersensitivity to its components. Common side effects may include drowsiness, dry mouth, and gastrointestinal disturbances. Dosage should be as prescribed by a healthcare professional, and patients are advised to avoid activities requiring mental alertness until the drug’s effects are known. Gemvert offers a reliable therapeutic option for managing vestibular disorders and motion sickness symptoms.